Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination with an Antidepressant in the Treatment of Major Depressive Disorders - PEARL
Study identifier:D1448C00006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination with an Antidepressant in the Treatment of Patients with Major Depressive Disorder with Inadequate Response to an Antidepressant Treatment (PEARL STUDY)
Medical condition
Major depressive disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine fumarate
Sex
All
Actual Enrollment
450
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Apr 2006
Primary Completion Date: -
Study Completion Date: 01 Jul 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Seroquel Medical Science Director
AstraZeneca
